Description

At ADA 2026, the GLP‑1 pipeline took center stage, showcasing next‑generation incretin therapies with transformative efficacy and new formulations. Retatrutide, a once‑weekly GLP‑1/GIP/glucagon triple agonist, achieved headline TRIUMPH‑1 results: mean weight loss of 28.3% at 80 weeks and 45.3% of top‑dose participants losing ≥30%, approaching bariatric ranges; glycaemic reductions in TRANSCEND‑T2D‑1 reached A1C falls of up to 2.0%. A new safety signal—higher urinary tract infection rates—was noted. CagriSema (cagrilintide+semaglutide) met A1C and weight endpoints across REIMAGINE trials and is under regulatory review. Orforglipron, an oral small‑molecule GLP‑1, promises easier administration and improved access. Collectively, these agents raise the efficacy ceiling for pharmacologic obesity treatment and signal broader therapeutic options for CKM practice. However, emerging safety signals with potent multiagonists underscore the need for vigilant post‑marketing surveillance as approvals expand real‑world use.